ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Study bodes well for low-carb eaters

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Omega Fix for Obesity: How the Right Fats Fight Fat

Potential of Quercetin in the Treatment of Melanoma

How Pomegranate May Protect Against Cancer

Trimming the spare tire: Canola oil may cut belly fat

 
Print Page
Email Article

Bladder Cancer Survival Rate Jumps

  [ 81 votes ]   [ Discuss This Article ]
www.ProHealth.com • August 27, 2003


HOUSTON –– Treating locally advanced bladder cancer with neoadjuvant chemotherapy –– chemotherapy before surgery –– can offer longer life to patients compared to the standard treatment of surgery alone, according to a study published in the August 28 issue of the New England Journal of Medicine.

In the 11-year study of 307 patients, conducted by the Southwest Oncology Group (SWOG) and led by an investigator at The University of Texas M. D. Anderson Cancer Center, researchers found that patients who received neoadjuvant chemotherapy lived an average of 31 months longer, and that those treated with surgery alone had a 66 percent greater chance of dying from bladder cancer than patients who had the combination therapy.

"This is an important advance, because the study shows a significant and clinically meaningful improvement in survival among patients who received chemotherapy before surgery," says the study's principal investigator, H. Barton Grossman, M.D., professor of urology at M. D. Anderson.

"Treatment of this disease varies across the country, but we believe neoadjuvant chemotherapy should be used more frequently to treat patients with locally advanced bladder cancer," he says.

Bladder cancer, considered a worldwide problem, is a leading tobacco-related cancer. In the United States, it is the fourth most common cancer in men and the eighth in women. According to the American Cancer Society, approximately 57,000 people are expected to be diagnosed with bladder cancer in this country in 2003 and an estimated 12,500 people will die of the disease.

Because of its tendency to spread, researchers have investigated a number of therapies to treat transitional cell bladder cancer (the most common form of the disease) which has invaded the bladder muscle and, therefore, is considered locally advanced. Studies to date have found that radiation therapy before surgery did not improve outcome.

With chemotherapy proving beneficial in patients with bladder cancer that had spread to other organs, SWOG began a randomized study in 1987 testing survival in patients who received surgery alone, versus patients treated with a three cycles of a chemotherapy combination known as M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) before surgery. The study included 126 institutions around the country.

In all, 154 patients were assigned to receive surgery as primary treatment, and 153 patients received combination therapy. At the end of the study, researchers found that median survival between the two groups was significantly different. Patients treated with surgery lived a median of 41 months, compared to 77 months in patients treated with chemotherapy followed by surgery.

When the investigators looked at death rates from bladder cancer, they concluded that more patients treated with surgery alone died of the disease, and they died at a faster rate –– 77 patients died of bladder cancer in the surgery arm, compared to 54 in the combination treatment group. Patients treated with surgery alone had a 66 percent greater risk of dying from bladder cancer than patients who received neoadjuvant chemotherapy, according to the research team.

When overall death rates were considered –– death from any cause, not just bladder cancer –– the results were not as significant, Grossman says. After follow-up of more than eight years in each group, 90 deaths occurred in the combination therapy compared with 100 deaths in the group treated with surgery, meaning that patients who received surgery had a 33 percent greater chance of dying than patients treated with combination therapy, says Grossman. "These patients are generally older and may die of other causes, but the chance of surviving was higher in the neoadjuvant group," he says.

Patients who did best of all were those who had no cancer left in the bladder at the time of surgery, the researchers concluded. At the time of surgery, significantly more patients (38 percent) had no evidence of cancer remaining in bladder tissue, compared to 15 percent of patients who did not have prior chemotherapy.

"There were significantly more patients in the neoadjuvant group who had no residual disease compared to the surgery group and those are the patients that have much better survival. The chemotherapy effectively down-staged their cancer," says Grossman. "Ten years after treatment, some of those patients are still alive, so neoadjuvant chemotherapy before surgery provided a cure for them."



The study was supported by grants from the National Cancer Institute.



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Vitamin D3 Extreme™ Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
The New Dual Activation Pain Relief Cream The New Dual Activation Pain Relief Cream
Stop Bacteria With Nature's Antibiotics Stop Bacteria With Nature's Antibiotics
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
Secret Nutrient for Radiant Skin Secret Nutrient for Radiant Skin

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map